741
Participants
Start Date
July 31, 2014
Primary Completion Date
June 30, 2015
Study Completion Date
September 30, 2015
SOF/VEL
400/100 mg FDC tablet administered orally once daily
Placebo
Tablet administered orally once daily
Brussels
Antwerp
Kortrijk
New York
The Bronx
Berlin
Marseille
Pittsburgh
Pittsburgh
Philadelphia
Hamburg
Lutherville
Atlanta
Hanover
Toulouse
Pessac
Düsseldorf
Hufelandstr
Indianapolis
Detroit
Florence
Cologne
Lille
Frankfurt am Main
Chicago
Clermont-Ferrand
Lyon
San Giovanni Rotondo
Paris
San Antonio
Aurora
München
Limoges
Los Angeles
Los Angeles
Los Angeles
Clichy
San Diego
San Diego
Créteil
Villejuif
Little Rock
Long Beach
Palo Alto
Sacramento
Jacksonville
Miami
Orlando
Wellington
Marietta
Baltimore
Germantown
Nashville
Norfolk
Richmond
Hong Kong
San Giovanni Rotondo
San Juan
Gainesville
Boston
Providence
Calgary
Edmonton
Vancouver
Vancouver
Ottawa
Montreal
Toronto
Berlin
Plymouth
Portsmouth
Glasgow
London
London
London
London
London
Manchester
Nottingham
Oxford
Lead Sponsor
Gilead Sciences
INDUSTRY